Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Cash (2016 - 2025)

Historic Change in Cash for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to -$253.0 million.

  • United Therapeutics' Change in Cash fell 22764.88% to -$253.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 14791.57%. This contributed to the annual value of $489.5 million for FY2024, which is 9858.01% up from last year.
  • As of Q3 2025, United Therapeutics' Change in Cash stood at -$253.0 million, which was down 22764.88% from -$306.8 million recorded in Q2 2025.
  • United Therapeutics' Change in Cash's 5-year high stood at $202.7 million during Q1 2025, with a 5-year trough of -$306.8 million in Q2 2025.
  • For the 5-year period, United Therapeutics' Change in Cash averaged around $31.7 million, with its median value being $43.8 million (2024).
  • Within the past 5 years, the most significant YoY rise in United Therapeutics' Change in Cash was 188571.43% (2023), while the steepest drop was 43149.17% (2023).
  • Over the past 5 years, United Therapeutics' Change in Cash (Quarter) stood at -$13.7 million in 2021, then skyrocketed by 59.12% to -$5.6 million in 2022, then surged by 1885.71% to $100.0 million in 2023, then surged by 43.3% to $143.3 million in 2024, then crashed by 276.55% to -$253.0 million in 2025.
  • Its last three reported values are -$253.0 million in Q3 2025, -$306.8 million for Q2 2025, and $202.7 million during Q1 2025.